dr. goodman on contributing factors to the lack of development in ptcl treatment
Published 4 years ago • 450 plays • Length 0:55Download video MP4
Download video MP3
Similar videos
-
1:01
dr. goodman on the importance of the echelon-2 data in ptcl
-
2:27
the current standard of care for patients with ptcl
-
0:46
dr. goodman on the need for molecular subtyping in t-cell lymphomas
-
2:07
dr. goodman on the role of transplant in t-cell lymphoma
-
5:15
a stone in the bile duct called choledocholithiasis.
-
1:01:23
targeting the podocyte as a treatment approach for fsgs
-
4:35
understanding peripheral t-cell lymphoma
-
2:30
ptcl treatment in the community setting
-
1:11
dr. goodman on the role of pd-1 inhibitors in t-cell lymphomas
-
3:51
treating patients with cd30-positive ptcl
-
3:19
the impact of brentuximab vedotin as ptcl treatment
-
4:08
the current unmet needs in ptcl treatment and prospects
-
0:45
latest developments in ptcl treatment
-
1:35
long-term outcomes for patients with ptcl: 10-year follow-up analysis
-
0:51
the need for novel agents for the treatment of ptcl
-
1:34
the future of valemetostat in ptcl
-
27:29
ptcl new targets in pipeline? dr riad dada ksa
-
1:21
major unmet needs in ptcl
-
5:34
romidepsin plus lenalidomide for patients with previously untreated ptcl
-
4:39
ptcl community treatment and future advancements
-
4:50
patterns of treatment for ptcl in the community setting
-
7:48
novel agents and chemotherapy regimens in ptcl